NCT05611931Phase 3Active not recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Study sponsor: Karyopharm Therapeutics Inc · KPTI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-05-22Actual
Enrollment · participants257Actual
Source updated2026-10-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Aug 2026. After: 22 May 2026.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 276 participants (planned). After: 257 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview